Cargando…

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa

Around 2.5 million HIV-infected individuals failing first-line therapy qualify for boosted protease inhibitor (bPI)-based second-line therapy globally. Major resistance mutations are rarely present at treatment failure in patients receiving bPI and the determinants of failure in these patients remai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sutherland, Katherine A., Goodall, Ruth L., McCormick, Adele, Kapaata, Anne, Lyagoba, Fred, Kaleebu, Pontiano, Thiltgen, Geant, Gilks, Charles F., Spyer, Moira, Kityo, Cissy, Pillay, Deenan, Dunn, David, Gupta, Ravindra K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2015
Materias:	Sequence Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675176/ https://www.ncbi.nlm.nih.gov/pubmed/26258548 http://dx.doi.org/10.1089/aid.2015.0138

Ejemplares similares

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
por: Sutherland, Katherine A., et al.
Publicado: (2015)

Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
por: Sutherland, Katherine A., et al.
Publicado: (2016)

Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
por: Pillay, D, et al.
Publicado: (2010)

Hepatitis B serological markers and plasma DNA concentrations
por: Price, Huw, et al.
Publicado: (2017)

Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa
por: Goodall, Ruth L., et al.
Publicado: (2017)

High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial
por: Kityo, Cissy, et al.
Publicado: (2014)

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag–protease genes
por: Sutherland, Katherine A., et al.
Publicado: (2014)

The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data
por: Dolling, David I., et al.
Publicado: (2017)

Role of Gag in HIV Resistance to Protease Inhibitors
por: Clavel, François, et al.
Publicado: (2010)

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults
por: Namakoola, Ivan, et al.
Publicado: (2016)

Human Immunodeficiency Virus gag and protease: partners in resistance
por: Fun, Axel, et al.
Publicado: (2012)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

Deep Sequencing of Protease Inhibitor Resistant HIV Patient Isolates Reveals Patterns of Correlated Mutations in Gag and Protease
por: Flynn, William F., et al.
Publicado: (2015)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs
por: Su, Chinh Tran-To, et al.
Publicado: (2019)

Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells
por: Titanji, Boghuma Kabisen, et al.
Publicado: (2013)

Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors
por: Codoñer, Francisco M, et al.
Publicado: (2017)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites
por: Kraus, Benjamin, et al.
Publicado: (2011)

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness
por: Martin, Supang A., et al.
Publicado: (2021)

Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors
por: Kayondo, Jonathan K., et al.
Publicado: (2015)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

P20-10. Differences in patterns of Gag-induced immunogenetic pressure occur between clades A and D chronic HIV-1 infection in a Ugandan population
por: Serwanga, J, et al.
Publicado: (2009)

HIV-1 Gag-Pol Sequences from Ugandan Early Infections Reveal Sequence Variants Associated with Elevated Replication Capacity
por: Kapaata, Anne, et al.
Publicado: (2021)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Identification of the protease cleavage sites in a reconstituted Gag polyprotein of an HERV-K(HML-2) element
por: George, Maja, et al.
Publicado: (2011)

Gag-Pol Transframe Domain p6* Is Essential for HIV-1 Protease-Mediated Virus Maturation
por: Yu, Fu-Hsien, et al.
Publicado: (2015)

Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV
por: Climaco-Arvizu, Samantha, et al.
Publicado: (2022)

554. Does Protease Inhibitor (PI) Monotherapy Select Primary PI Resistance?
por: Saling, Christopher, et al.
Publicado: (2018)

Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa
por: Farinre, Omotayo, et al.
Publicado: (2021)

Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis
por: Collier, Dami, et al.
Publicado: (2017)

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy
por: Pérez-Valero, Ignacio, et al.
Publicado: (2013)

Placement of p6pol between tandem repeat HIV-1 protease domains reduces Gag cleavage efficiency
por: Chou, Tin-An, et al.
Publicado: (2013)

Frequencies of Gag-restricted T-cell escape “footprints” differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B alleles()
por: Serwanga, Jennifer, et al.
Publicado: (2015)

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814
por: Li, Jian, et al.
Publicado: (2022)

Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis
por: Mathis, Sandra, et al.
Publicado: (2011)

Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation
por: Torres, Berta, et al.
Publicado: (2014)

Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor
por: Hu, Xiaohui, et al.
Publicado: (2022)

Proteases
por: Ward, O.P.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qrqokniep7j0bhm6u90hedsmlu